Patient adherence as a predictor of acute and long-term outcomes in concentrated exposure treatment for difficult-to-treat obsessive-compulsive disorder.
Adherence
B4DT
Difficult-to-treat
ERP
Group
OCD
Work- and social functioning
cET
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
received:
20
04
2023
accepted:
19
04
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
Exposure and response prevention (ERP) is considered the first-line psychotherapy for obsessive-compulsive disorder (OCD). Substantial research supports the effectiveness of ERP, yet a notable portion of patients do not fully respond while others experience relapse. Understanding poor outcomes such as these necessitates further research. This study investigated the role of patient adherence to ERP tasks in concentrated exposure treatment (cET) in a sample who had previously not responded to treatment or relapsed. The present study included 163 adults with difficult-to-treat OCD. All patients received cET delivered during four consecutive days. Patients' treatment adherence was assessed using the Patient EX/RP Adherence Scale (PEAS-P) after the second and third day of treatment. OCD severity was evaluated at post-treatment, 3-month follow-up, and 1-year follow-up by independent evaluators. PEAS-P scores during concentrated treatment were associated with OCD-severity at post-treatment, 3-month follow-up, and 1-year follow-up. Moreover, PEAS-P scores predicted 12-month OCD severity adjusting for relevant covariates. Adherence also predicted work- and social functioning at 1-year follow-up. These results indicate that ERP adherence during the brief period of cET robustly relates to improvement in OCD symptoms and functioning in both the short and long term. Assessing adherence might identify patients at risk of poor outcomes, while improving adherence may enhance ERP for treatment resistant patients. ClinicalTrials.gov identifier: NCT02656342.
Sections du résumé
BACKGROUND
BACKGROUND
Exposure and response prevention (ERP) is considered the first-line psychotherapy for obsessive-compulsive disorder (OCD). Substantial research supports the effectiveness of ERP, yet a notable portion of patients do not fully respond while others experience relapse. Understanding poor outcomes such as these necessitates further research. This study investigated the role of patient adherence to ERP tasks in concentrated exposure treatment (cET) in a sample who had previously not responded to treatment or relapsed.
METHOD
METHODS
The present study included 163 adults with difficult-to-treat OCD. All patients received cET delivered during four consecutive days. Patients' treatment adherence was assessed using the Patient EX/RP Adherence Scale (PEAS-P) after the second and third day of treatment. OCD severity was evaluated at post-treatment, 3-month follow-up, and 1-year follow-up by independent evaluators.
RESULTS
RESULTS
PEAS-P scores during concentrated treatment were associated with OCD-severity at post-treatment, 3-month follow-up, and 1-year follow-up. Moreover, PEAS-P scores predicted 12-month OCD severity adjusting for relevant covariates. Adherence also predicted work- and social functioning at 1-year follow-up.
CONCLUSIONS
CONCLUSIONS
These results indicate that ERP adherence during the brief period of cET robustly relates to improvement in OCD symptoms and functioning in both the short and long term. Assessing adherence might identify patients at risk of poor outcomes, while improving adherence may enhance ERP for treatment resistant patients.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier: NCT02656342.
Identifiants
pubmed: 38689256
doi: 10.1186/s12888-024-05780-6
pii: 10.1186/s12888-024-05780-6
doi:
Banques de données
ClinicalTrials.gov
['NCT02656342']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
327Informations de copyright
© 2024. The Author(s).
Références
American Psychiatric Association. Diagnostic and statistical Manual of Mental disorders. American Psychiatric Pub; 2013.
Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–84.
pubmed: 22865617
pmcid: 4005415
doi: 10.1002/mpr.1359
Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53–63.
pubmed: 18725912
doi: 10.1038/mp.2008.94
Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1999;56(2):121–7.
pubmed: 10025435
doi: 10.1001/archpsyc.56.2.121
Eisen JL, Sibrava NJ, Boisseau CL, Mancebo MC, Stout RL, Pinto A, Rasmussen SA. Five-year course of obsessive-compulsive disorder: predictors of remission and relapse. J Clin Psychiatry. 2013;74(3):7286.
doi: 10.4088/JCP.12m07657
Macy AS, Theo JN, Kaufmann SCV, Ghazzaoui RB, Pawlowski PA, Fakhry HI, et al. Quality of life in obsessive compulsive disorder. CNS Spectr. 2013;18(1):21–33.
pubmed: 23279901
doi: 10.1017/S1092852912000697
Solem S, Håland ÅT, Hagen K, Launes G, Hansen B, Vogel PA, Himle JA. Interpersonal style in obsessive compulsive disorder. Cogn Behav Therapist. 2015;8.
Jacoby RJ, Leonard RC, Riemann BC, Abramowitz JS. Predictors of quality of life and functional impairment in obsessive-compulsive disorder. Compr Psychiatry. 2014;55(5):1195–202.
pubmed: 24746527
doi: 10.1016/j.comppsych.2014.03.011
Eisen JL, Mancebo MA, Pinto A, Coles ME, Pagano ME, Stout R, Rasmussen SA. Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry. 2006;47(4):270–5.
pubmed: 16769301
pmcid: 2633465
doi: 10.1016/j.comppsych.2005.11.006
Koran LM, Simpson HB. Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association; 2013.
Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016;3(8):730–9.
pubmed: 27318812
pmcid: 4967667
doi: 10.1016/S2215-0366(16)30069-4
Öst LG, Havnen A, Hansen B, Kvale G. Cognitive behavioral treatments of obsessive-compulsive disorder. A systematic review and Meta-analysis of studies published 1993–2014. Clin Psychol Rev. 2015;40:156–69.
pubmed: 26117062
doi: 10.1016/j.cpr.2015.06.003
Abramowitz JS. The psychological treatment of obsessive-compulsive disorder. Can J Psychiatry. 2006;51(7):407–16.
pubmed: 16838822
doi: 10.1177/070674370605100702
Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(2):269–76.
pubmed: 16566623
doi: 10.4088/JCP.v67n0214
Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12–9.
pubmed: 2002127
doi: 10.1037/0022-006X.59.1.12
Abramowitz JS. Does cognitive-behavioral therapy cure obsessive-compulsive disorder? A meta-analytic evaluation of clinical significance. Behav Ther. 1998;29(2):339–55.
doi: 10.1016/S0005-7894(98)80012-9
Olatunji BO, Davis ML, Powers MB, Smits JA. Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators. J Psychiatr Res. 2013;47(1):33–41.
pubmed: 22999486
doi: 10.1016/j.jpsychires.2012.08.020
Simpson HB, Foa EB, Wheaton MG, Gallagher T, Gershkovich M, Schmidt AB, et al. Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder. Behav Res Ther. 2021;143:103890.
pubmed: 34089924
pmcid: 8241471
doi: 10.1016/j.brat.2021.103890
Külz AK, Landmann S, Schmidt-Ott M, Zurowski B, Wahl-Kordon A, Voderholzer U. Long-term follow-up of cognitive-behavioral therapy for obsessive-compulsive disorder (OCD): Symptom Severity and the role of exposure 8–10 years after Inpatient Treatment. J Cogn Psychother. 2020.
Jónsson H, Kristensen M, Arendt M. Intensive cognitive behavioural therapy for obsessive-compulsive disorder: a systematic review and Meta-analysis. J Obsessive-Compulsive Relat Disord. 2015;6:83–96.
doi: 10.1016/j.jocrd.2015.04.004
Abramowitz JS, Foa EB, Franklin ME. Exposure and Ritual Prevention for obsessive-compulsive disorder: effects of Intensive Versus twice-Weekly Sessions. J Consult Clin Psychol. 2003;71(2):394–8.
pubmed: 12699033
doi: 10.1037/0022-006X.71.2.394
Oldfield VB, Salkovskis PM, Taylor T. Time-intensive cognitive behaviour therapy for obsessive-compulsive disorder: a case series and matched comparison group. Br J Clin Psychol. 2011;50(1):7–18.
pubmed: 21332517
doi: 10.1348/014466510X490073
Storch EA, Merlo LJ, Lehmkuhl H, Geffken GR, Jacob M, Ricketts E, et al. Cognitive-behavioral therapy for obsessive–compulsive disorder: a non-randomized comparison of intensive and weekly approaches. J Anxiety Disord. 2008;22(7):1146–58.
pubmed: 18242950
doi: 10.1016/j.janxdis.2007.12.001
Kvale G, Hansen B, Bjorgvinsson T, Bortveit T, Hagen K, Haseth S, et al. Successfully treating 90 patients with obsessive compulsive disorder in eight days: the Bergen 4-Day treatment. BMC Psychiatry. 2018;18(1):323.
pubmed: 30286745
pmcid: 6172736
doi: 10.1186/s12888-018-1887-4
Launes G, Hagen K, Sunde T, Öst LG, Klovning I, Laukvik IL, et al. A Randomized Controlled Trial of Concentrated ERP, Self-Help and Waiting List for obsessive- compulsive disorder: the Bergen 4-Day treatment. Front Psychol. 2019;10:2500.
pubmed: 31803089
pmcid: 6873786
doi: 10.3389/fpsyg.2019.02500
Launes G, Hagen K, Öst LG, Solem S, Hansen B, Kvale G. The Bergen 4-Day treatment (B4DT) for obsessive-compulsive disorder: outcomes for patients treated after initial waiting list or self-help intervention. Front Psychol. 2020;11:982.
pubmed: 32528372
pmcid: 7266968
doi: 10.3389/fpsyg.2020.00982
Launes G, Laukvik IL, Sunde T, Klovning I, Hagen K, Solem S, et al. The Bergen 4-Day treatment for obsessive-compulsive disorder: does it work in a New Clinical setting? Front Psychol. 2019;10:1069.
pubmed: 31164848
pmcid: 6534081
doi: 10.3389/fpsyg.2019.01069
Davíðsdóttir SD, Sigurjónsdóttir O, Ludvigsdóttir SJ, Hansen B, Laukvik IL, Hagen K et al. Implementation of the Bergen 4-day treatment for OCD in Iceland. Clin Neuropsychiatry. 2019.
Hansen B, Hagen K, Öst LG, Solem S, Kvale G. The Bergen 4-Day OCD treatment delivered in a Group setting: 12-Month Follow-Up. Front Psychol. 2018;9:639.
pubmed: 29774005
pmcid: 5943612
doi: 10.3389/fpsyg.2018.00639
Hansen B, Kvale G, Hagen K, Havnen A, Öst LG. The Bergen 4-Day treatment for OCD: four years Follow-Up of concentrated ERP in a clinical Mental Health setting. Cogn Behav Ther. 2019;48(2):89–105.
pubmed: 30088441
doi: 10.1080/16506073.2018.1478447
Kvale G, Hansen B, Hagen K, Abramowitz JS, Bortveit T, Craske MG, et al. Effect of D-Cycloserine on the effect of concentrated exposure and response Prevention in difficult-to-treat obsessive-compulsive disorder: a Randomized Clinical Trial. JAMA Netw Open. 2020;3(8):e2013249.
pubmed: 32789516
pmcid: 7426745
doi: 10.1001/jamanetworkopen.2020.13249
Knopp J, Knowles S, Bee P, Lovell K, Bower P. A systematic review of predictors and moderators of response to psychological therapies in OCD: do we have enough empirical evidence to target treatment? Clin Psychol Rev. 2013;33(8):1067–81.
pubmed: 24077387
doi: 10.1016/j.cpr.2013.08.008
McDonald S, Melkonian M, Karin E, Dear BF, Titov N, Wootton BM. Predictors of response to cognitive behavioural therapy (CBT) for individuals with obsessive-compulsive disorder (OCD): a systematic review. Behav Cogn Psychother. 2023:1–18.
Simpson HB, Maher MJ, Wang Y, Bao Y, Foa EB, Franklin M. Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder. J Consult Clin Psychol. 2011;79(2):247–52.
pubmed: 21355639
pmcid: 3891521
doi: 10.1037/a0022659
Simpson HB, Marcus SM, Zuckoff A, Franklin M, Foa EB. Patient adherence to cognitive-behavioral therapy predicts long-term outcome in obsessive-compulsive disorder. J Clin Psychiatry. 2012;73(9):1265–6.
pubmed: 23059155
pmcid: 3951095
doi: 10.4088/JCP.12l07879
Wheaton MG, Galfalvy H, Steinman SA, Wall MM, Foa EB, Simpson HB. Patient adherence and treatment outcome with exposure and response Prevention for OCD: which components of Adherence Matter and who becomes well? Behav Res Ther. 2016;85:6–12.
pubmed: 27497840
pmcid: 5031484
doi: 10.1016/j.brat.2016.07.010
Ojalehto HJ, Abramowitz JS, Hellberg SN, Buchholz JL, Twohig MP. Adherence to exposure and Response Prevention as a predictor of improvement in obsessive-compulsive symptom dimensions. J Anxiety Disord. 2020;72:102210.
pubmed: 32208231
doi: 10.1016/j.janxdis.2020.102210
Tjelle K, Opstad HB, Solem S, Launes G, Hansen B, Kvale G, Hagen K. Treatment adherence as predictor of outcome in concentrated exposure treatment for obsessive-compulsive disorder. Front Psychiatry. 2021;12.
Grøtte T, Hansen B, Haseth S, Vogel PA, Guzey IC, Solem S. Three-week Inpatient Treatment of Obsessive-compulsive disorder: a 6-Month Follow-Up study. Front Psychol. 2018;9:620.
pubmed: 29760673
pmcid: 5936770
doi: 10.3389/fpsyg.2018.00620
Håland ÅT, Vogel PA, Lie B, Launes G, Pripp AH, Himle JA. Behavioural group therapy for obsessive–compulsive disorder in Norway. An open community-based trial. Behav Res Ther. 2010;48(6):547–54.
pubmed: 20359692
doi: 10.1016/j.brat.2010.03.005
Vogel PA, Solem S, Hagen K, Moen EM, Launes G, Haland AT, et al. A pilot randomized controlled trial of videoconference-assisted treatment for obsessive-compulsive disorder. Behav Res Ther. 2014;63:162–8.
pubmed: 25461792
doi: 10.1016/j.brat.2014.10.007
Foa EB, Yadin E, Lichner TK. Exposure and response Prevention for OCD: Therapist Guide. London: Oxford University Press; 2012.
Simpson HB, Maher M, Page JR, Gibbons CJ, Franklin ME, Foa EB. Development of a patient adherence scale for exposure and response Prevention Therapy. Behav Ther. 2010;41(1):30–7.
pubmed: 20171325
doi: 10.1016/j.beth.2008.12.002
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive compulsive scale. I. Development, Use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006–11.
pubmed: 2684084
doi: 10.1001/archpsyc.1989.01810110048007
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive compulsive scale. II. Validity. Arch Gen Psychiatry. 1989;46(11):1012–6.
pubmed: 2510699
doi: 10.1001/archpsyc.1989.01810110054008
Mundt JC, Marks IM, Shear MK, Greist JH. The work and Social Adjustment Scale: a simple measure of impairment in Functioning. Br J Psychiatry. 2002;180(5):461–4.
pubmed: 11983645
doi: 10.1192/bjp.180.5.461
Cella M, Sharpe M, Chalder T. Measuring disability in patients with chronic fatigue syndrome: reliability and validity of the work and Social Adjustment Scale. J Psychosom Res. 2011;71(3):124–8.
pubmed: 21843745
doi: 10.1016/j.jpsychores.2011.02.009
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.
pubmed: 16717171
doi: 10.1001/archinte.166.10.1092
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.
pubmed: 11556941
pmcid: 1495268
doi: 10.1046/j.1525-1497.2001.016009606.x
Wheaton MG, Patel SR, Andersson E, Rück C, Simpson HB. Predicting Treatment outcomes from internet-based cognitive behavior therapy for obsessive–compulsive disorder. Behav Ther. 2021;52(1):77–85.
pubmed: 33483126
doi: 10.1016/j.beth.2020.02.003